THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 114 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,963 | -16.6% | 3,472 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $35,935 | -21.5% | 3,472 | -14.9% | 0.00% | 0.0% |
| Q4 2022 | $45,755 | +23.8% | 4,078 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $36,947 | -5.2% | 4,078 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $38,986 | -71.3% | 4,078 | -66.8% | 0.00% | -50.0% |
| Q4 2021 | $135,926 | +143.9% | 12,301 | +63.3% | 0.00% | +100.0% |
| Q3 2021 | $55,737 | -79.5% | 7,532 | -43.4% | 0.00% | -75.0% |
| Q1 2021 | $271,718 | +7.3% | 13,313 | -6.6% | 0.00% | 0.0% |
| Q4 2020 | $253,276 | -15.3% | 14,253 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $299,170 | +5.1% | 14,253 | -2.5% | 0.01% | 0.0% |
| Q3 2019 | $284,681 | +19.3% | 14,614 | 0.0% | 0.01% | +25.0% |
| Q2 2019 | $238,647 | -28.0% | 14,614 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $331,299 | -11.4% | 14,614 | 0.0% | 0.01% | -14.3% |
| Q4 2018 | $373,972 | -40.2% | 14,614 | -20.6% | 0.01% | +75.0% |
| Q2 2014 | $625,000 | – | 18,407 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Woodford Investment Management Ltd | 10,898,879 | $264,297,000 | 23.51% |
| Foundation Asset Management, LP | 399,537 | $9,689,000 | 3.59% |
| Cormorant Asset Management, LP | 1,300,000 | $31,525,000 | 2.35% |
| Baupost Group | 9,309,168 | $225,747,000 | 2.18% |
| Old West Investment Management, LLC | 109,320 | $2,651,000 | 1.53% |
| SENZAR ASSET MANAGEMENT, LLC | 187,856 | $4,555,000 | 1.44% |
| Chescapmanager LLC | 350,631 | $8,503,000 | 1.27% |
| Virtus ETF Advisers LLC | 32,989 | $800,000 | 0.69% |
| Rock Springs Capital Management LP | 652,600 | $15,826,000 | 0.68% |
| NJ State Employees Deferred Compensation Plan | 34,142 | $828,000 | 0.15% |